Ontwikkeling van KRAS/ PDE6D moleculaire lijmen om KRAS te remmen door nucleo-cytoplasmatische sequestratie
ExoRAS: Het gebruik van exosomen betrokken in intercellulaire communicatie om KRAS signalering te blokkeren en drug resistentie in multipel myeloom te bestrijden.
Voorspellende biomarkeranalyse bij standaard mCRC KRAS patiënten die in een eerste fase met Erbitux (Cetixumab) werden behandeld in combinatie met traditionele chemotherapie binnen de dagelijkse klinische praktijk in België .
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
The prognostic value of KRAS, NRAS, BRAF and DNA mismatch repair (MMR) status in left- and right-sided metastatic colorectal cancer (mCRC): A Belgian population-based study
KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?
Data from: Canonical correlations reveal adaptive loci and phenotypic responses to climate in perennial ryegrass